Connetics gets sector perform rating from RBC

RBC Capital Markets analyst Ken Trbovich rated Connetics at sector perform on news that Paul Capital will fund development of 16 generic dermatology products by Glenmark Pharmaceuticals, Inc. Shares of the Palo Alto, Calif.-based pharmaceutical company were up 71 cents, or 5.88%, at $12.79 on volume of 562,807 shares versus the three-month running average of 555,665 shares. (Nasdaq: CNCT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.